ACST Stock – (NASDAQ: ACST) is giving an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is giving an update on the usage of the “at the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering program under which Acasti may well issue and market from time to time its everyday shares having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares were marketed at prevailing market rates averaging US$1.0747 per share. No securities were sold in the facilities of the TSXV or perhaps, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will deliver the Company with extra freedom in its ongoing review process to enjoy and evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescribed drugs using OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical evidence of safety as well as efficacy for lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for individuals with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release that aren’t statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, along with other unknown elements that could cause the actual outcomes of Acasti to be materially different from historical results and even from any future outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, people are actually urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the particular date of this particular press release. Forward-looking statements in that press release include, but aren’t limited to, information or statements concerning Acasti’s strategy, future operations and its review of strategic alternatives.
The forward looking statements contained in this specific press release are expressly qualified in their entirety by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor area of Acasti’s site at www.acastipharma.com. All forward looking statements in this press release are available as of the day of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward looking statements whether as a consequence of information that is new , future events or even otherwise, except as needed by law. The forward looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the usage